© 2004 European Society of Cardiology
N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea
a Department of Internal Medicine Haderslev Hospital, 6100 Haderslev, Denmark
b Department of Clinical Chemistry Odense University Hospital, Odense, Denmark
c Department of Cardiology Aarhus University Hospital, Skejby, Aarhus, Denmark
* Corresponding author. Tel.: +45-74273493; fax: +45-74273505. E-mail address: lene.svendstrup{at}dadlnet.dk
 |
Abstract |
|---|
Aim: Evaluation of N-terminal pro-brain natriuretic peptide (NT-proBNP) to confirm or disprove heart failure in community patients complaining of dyspnoea.
Methods and results: General practitioners referred 345 consecutive patients complaining of dyspnoea to our hospital-based clinic, where a diagnosis was established based on a combined programme for heart and lung diseases including echocardiography. The level of NT-proBNP in plasma was also measured. The mean (S.D.) concentration of NT-proBNP in patients with heart failure was significantly higher, 189 (270) pmol/l in patients with heart failure (n=81), than in patients with non-cardiac dyspnoea (n=264), 17 (38) pmol/l (P<0.001). In patients 
50 years NT-proBNP <11 pmol/l for men and <17 pmol/l for women excluded heart failure with a negative predictive value of 97% while the positive predictive value was 53%, the sensitivity 95% and the specificity 68%. Areas under receiver operator characteristic curves for men and women were 0.93 and 0.90, respectively.
Conclusion: In a relevant setting of primary care patients complaining of dyspnoea, NT-proBNP seems promising for disproval of heart failure, and this test may reduce the need for echocardiographic screening with 50%. However, the discrimination levels of NT-proBNP found in this study may need prospective confirmation, before the test can be generally recommended.
Key Words: NT-proBNP • Brain natriuretic peptide • Heart failure • Dyspnoea
Received May 27, 2003; Revised July 28, 2003; Accepted October 8, 2003
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. S. Rubino, F. Onorati, G. Santarpino, E. Pasceri, G. Santarpia, L. Cristodoro, G. F. Serraino, and A. Renzulli Neurohormonal and echocardiographic results after CorCap and mitral annuloplasty for dilated cardiomyopathy. Ann. Thorac. Surg., September 1, 2009; 88(3): 719 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Pfister and C. A. Schneider ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: application of natriuretic peptides Eur. Heart J., February 1, 2009; 30(3): 382 - 383. [Full Text] [PDF]
|
|
|
|
 |
|
 J. C Kelder, F. H Rutten, and A. W Hoes Clinically relevant diagnostic research in primary care: the example of B-type natriuretic peptides in the detection of heart failure Fam. Pract., February 1, 2009; 26(1): 69 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rosenberg, M. Schou, F. Gustafsson, J. Badskjaer, and P. Hildebrandt Prognostic threshold levels of NT-proBNP testing in primary care Eur. Heart J., January 1, 2009; 30(1): 66 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. G. Rasmussen, S. H. Poulsen, E. Dupont, K. Ostergaard, G. Safikhany, and H. Egeblad Ergotamine-derived dopamine agonists and left ventricular function in Parkinson patients: systolic and diastolic function studied by conventional echocardiography, tissue Doppler imaging, and two-dimensional speckle tracking Eur J Echocardiogr, November 1, 2008; 9(6): 803 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Brune, H. A. Katus, J. Moecks, E. Spanuth, A. S. Jaffe, and E. Giannitsis N-Terminal Pro-B-Type Natriuretic Peptide Concentrations Predict the Risk of Cardiovascular Adverse Events from Antiinflammatory Drugs: A Pilot Trial Clin. Chem., July 1, 2008; 54(7): 1149 - 1157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Della Corte, G. Salerno, E. Chiosi, D. Iarussi, G. Santarpino, M. Miraglia, S. Naviglio, and M. De Feo Preoperative, postoperative and 1-year follow-up N-terminal pro-B-type natriuretic peptide levels in severe chronic aortic regurgitation: correlations with echocardiographic findings Interactive CardioVascular and Thoracic Surgery, June 1, 2008; 7(3): 419 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Green, A. Martinez-Rumayor, S. A. Gregory, A. L. Baggish, M. L. O'Donoghue, J. A. Green, K. B. Lewandrowski, and J. L. Januzzi Jr Clinical Uncertainty, Diagnostic Accuracy, and Outcomes in Emergency Department Patients Presenting With Dyspnea Arch Intern Med, April 14, 2008; 168(7): 741 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O.W. Nielsen, P.J. Cowburn, A. Sajadieh, J.J. Morton, H. Dargie, and T. McDonagh Value of BNP to estimate cardiac risk in patients on cardioactive treatment in primary care Eur J Heart Fail, December 1, 2007; 9(12): 1178 - 1185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H. Rutten, M.-J. M. Cramer, N. P.A. Zuithoff, J.-W. J. Lammers, W. Verweij, D. E. Grobbee, and A. W. Hoes Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease Eur J Heart Fail, June 1, 2007; 9(6-7): 651 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Herrmann, O. Taban-Shoma, U. Hubner, A. Pexa, H. Kilter, N. Umanskaya, R. Hans Straub, M. Bohm, and W. Herrmann Hyperhomocysteinemia and Myocardial Expression of Brain Natriuretic Peptide in Rats Clin. Chem., April 1, 2007; 53(4): 773 - 780. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H. Rutten, M.-J. M. Cramer, J.-W. J. Lammers, D. E. Grobbee, and A. W. Hoes Heart failure and chronic obstructive pulmonary disease: An ignored combination? Eur J Heart Fail, November 1, 2006; 8(7): 706 - 711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Aspromonte, V. Ceci, A. Chiera, C. Coletta, A. D'Eri, M. Feola, P. Giovinazzo, L. Milani, F. Noventa, A. B. Scardovi, et al. Rapid Brain Natriuretic Peptide Test and Doppler Echocardiography for Early Diagnosis of Mild Heart Failure Clin. Chem., September 1, 2006; 52(9): 1802 - 1808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Ambrosino and M Serradori Determining the cause of dyspnoea: linguistic and biological descriptors Chronic Respiratory Disease, July 1, 2006; 3(3): 117 - 122. [PDF]
|
|
|
|
 |
|
 R Sharma, D C Gaze, D Pellerin, R L Mehta, H Gregson, C P Streather, P O Collinson, and S J D Brecker Cardiac structural and functional abnormalities in end stage renal disease patients with elevated cardiac troponin T Heart, June 1, 2006; 92(6): 804 - 809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Terkelsen, B. L. Norgaard, J. F. Lassen, S. H. Poulsen, J. C. Gerdes, E. Sloth, L. B.-H. Gotzsche, F. K. Romer, L. Thuesen, T. T. Nielsen, et al. Potential significance of spontaneous and interventional ST-changes in patients transferred for primary percutaneous coronary intervention: observations from the ST-MONitoring in Acute Myocardial Infarction study (The MONAMI study) Eur. Heart J., February 1, 2006; 27(3): 267 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Tschope, M. Kasner, D. Westermann, R. Gaub, W. C. Poller, and H.-P. Schultheiss The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements Eur. Heart J., November 1, 2005; 26(21): 2277 - 2284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. I.W. Galasko, A. Lahiri, S. C. Barnes, P. Collinson, and R. Senior What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur. Heart J., November 1, 2005; 26(21): 2269 - 2276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Herrmann, I. Kindermann, S. Muller, T. Georg, M. Kindermann, M. Bohm, and W. Herrmann Relationship of Plasma Homocysteine with the Severity of Chronic Heart Failure Clin. Chem., August 1, 2005; 51(8): 1512 - 1515. [Full Text] [PDF]
|
|